\
&
Contact us
\
&
Contact us
This was 3 years ago
LocationHybrid event
A recent study by European Parliament's Panel for the Future of Science and Technology (STOA) investigated the feasibility of creating a large-scale European public infrastructure aimed at addressing vulnerabilities linked to the research, development, production and distribution of medicines.
On this basis, STOA is organising a panel discussion which will bring together experts from biomedical research, representatives of the pharmaceutical industry, and EU and international public health experts. The aim is to discuss the state-of-play of the EU's current pharmaceutical strategy and explore policy options for strengthening EU preparedness and response, including the feasibility of creating an advanced EU pharmaceutical infrastructure for the research and development of novel medicines and treatments. The panel discussion will be moderated by Karin SIPIDO, Head of Experimental Cardiology at KU Leuven, and the panel includes representatives from the European Commission. You can follow remotely or you can join the debate live in Brussels.
More information, the detailed programme and registration is available on the event's webpage.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Department of Economy, Science and Innovation of the Flemish government coordinates the Horizon 2020 Coordination and Support Action SAPHIRe, which started on 1 December 2018. The aim of the project is to secure the adoption of personalised medicine in all European regions, including sparsely populated and remote regions and regions with different innovation capacities.
The activities of SAPHIRe are complementary to the smart specialisation partnership on personalised medicine – S3P4PM, which is also coordinated by the Department of Economy, Science and Innovation.
